Loading
Total declarations
Companies
▲ Purchases (11 ops.)
▼ Sales (5 ops.)
Latest filing published 01 Nov 2017 for H-CYTE, INC., €13k.
Insider track record
Disclosed buys
11
Disclosed sells
5
Signal history
Closed purchases
Market purchases
11
Positive at T+90
50%
Median T+90
+59.4%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -6.1%Entry US$25.27 · Close at T+365 US$23.72
- +47.1%Entry US$0.68 · Close at T+365 US$1.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Larry W. Papasan: trading record in brief
Filings by Larry W. Papasan span 4 companies, the busiest being Biomimetic Therapeutics, Inc., Mimedx Group, Inc. and H-Cyte, Inc. We count 37 filings; the first trade dates from 11 May 2006 and the latest from 30 October 2017.
Both buying and selling appear: 11 purchases worth €130k, against 5 sales worth €96k. Taken together, the purchases exceed the sales by €34k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 9 share grants and 3 option exercises.
A typical purchase (the median) is worth €5,222.
The latest filing, published on 1 November 2017, reports a share grant of €13k in H-Cyte, Inc. The most recent open-market purchase was published on 29 March 2012, 5,322 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Larry W. Papasan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations32 total
12,821 shares@ US$1.1743.6% of flowCommon StockSEC:0001493152-17-012286:0
12,153 shares0Common StockSEC:0001376339-17-000099:0
21,739 shares@ US$1.3856.4% of flowCommon StockSEC:0001415889-17-000118:0
10,362 shares0Common StockSEC:0001376339-16-000177:0
21,429 shares0Common StockSEC:0001376339-16-000177:1
2,498 shares0Common StockSEC:0001376339-15-000073:0
2,498 shares0Common StockSEC:0001376339-15-000073:1
2,998 shares0Common StockSEC:0001376339-15-000073:2
5,958 shares@ US$10.09Common StockSEC:0001376339-15-000073:3
12,878 shares0Common StockSEC:0001376339-15-000063:0
3,567 shares0Common StockSEC:0001140361-14-036210:0
4,280 shares0Common StockSEC:0001140361-14-036210:1
1,427 shares0Common StockSEC:0001140361-14-036210:2
9,000 shares0Common StockSEC:0001140361-14-030223:0
69,517 sharesCommon StockSEC:0001209191-13-014338:2
2,000 shares@ US$2.32Common StockSEC:0001209191-12-020460:0
Canonical exit: 25 Jun 2012 (T+90)
3,000 shares@ US$2.32Common StockSEC:0001209191-12-020460:1
Canonical exit: 25 Jun 2012 (T+90)
2,400 shares@ US$2.34Common StockSEC:0001209191-12-020460:3
Canonical exit: 25 Jun 2012 (T+90)
1,000 shares@ US$25.86Common Shares of Beneficial InterestSEC:0001263994-11-000005:0
Canonical exit: 20 Mar 2012 (T+90)
2,500 shares@ US$5.71Common StockSEC:0001209191-11-034646:0
2,000 shares@ US$5.68Common StockSEC:0001209191-11-034646:1
2,000 shares@ US$5.70Common StockSEC:0001209191-11-034646:2
1,000 shares@ US$20.92Common Shares of Beneficial InterestSEC:0001281239-10-000001:0
9,720 shares@ US$3.63Common StockSEC:0001209191-10-043797:0
41,667 shares@ US$0.60Common StockSEC:0001140361-09-026955:0
Canonical exit: 17 Feb 2010 (T+90)
25 of 32 declarations
